Trump administration weighing future of CDC's HIV prevention division
WASHINGTON, March 18 (Reuters) - The U.S. health department said on Tuesday it is reviewing the Centers for Disease Control and Prevention's HIV prevention division for overlap with other agencies but no final decision had been made about its future.
The Department of Health and Human Services made the statement after the WSJ and NBC, citing unnamed sources, reported the division could be dismantled.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
The CDC's $1.3 billion Division of HIV Prevention is tasked with tracking infections across the United States and promoting testing and prevention, including the use of the HIV prevention medications, also known as PrEP.
Carl Schmid, the executive director of the HIV+Hepatitis Policy Institute in Washington, told Reuters he had been told by a government agency source that the division might be shut down and that a decision would be made this week on the funding of HIV prevention at the CDC.
Schmid, who co-chaired the Presidential Advisory Council of HIV/AIDS during President Donald Trump's first term, said he understood all of the division's funding is "up in the air".
HHS, which oversees the CDC, said in a statement it was looking at all divisions for potential overlap as part of Trump's broader efforts to restructure the federal government and that no final decision had been made on the CDC's HIV Prevention Division.
"If this decision is even made, this work would be continued elsewhere at HHS," a department official said.
Another HHS agency, the Health Resources and Services Administration, contains the Ryan White HIV/AIDS Program which provides HIV health services to low-income people.
The Trump administration's approach to HIV/AIDS policy is undergoing a broad shift. In January, the White House ordered an immediate halt to the distribution of HIV medications by U.S.-funded foreign clinics, disrupting treatment for millions worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
an hour ago
- The Independent
New preventative shot could ‘end HIV transmission'
The Food And Drug Administration has approved lenacapavir, a new twice-yearly injectable drug for HIV prevention. This new medication is the longest-lasting type of PrEP available, offering a significant advantage over daily pills or bi-monthly shots. Studies demonstrated lenacapavir's high effectiveness, with no HIV infections in participants receiving the shot in a study involving women and teen girls, and similar efficacy in gay men and gender-nonconforming people. Advocates believe the drug has the potential to end HIV transmission by expanding prevention opportunities and improving adherence, as users only need two injections per year. Despite its effectiveness, concerns remain about widespread access due to challenges in the U.S. healthcare system, including cuts to public health agencies and foreign aid for HIV initiatives.
The Independent
an hour ago
- The Independent
Groundbreaking single-dose vaccine found effective in preventing HIV
Scientists have developed a vaccine which provides a strong immune response against HIV in mice, an advance that could lead to potent single-dose vaccines for a range of infectious diseases. The vaccine candidate, when delivered along with two powerful adjuvants that stimulate the immune system, could produce a wide diversity of antibodies against the HIV virus, according to a new study published in the journal Science Translational Medicine. Researchers from the Massachusetts Institute of Technology in the US found that the vaccine accumulated in the lymph nodes and remained there for up to a month, allowing mice to build up a much greater number of antibodies against the HIV protein. This strategy may lead to new vaccines that only need to be taken once for a range of infectious diseases, including HIV or Sars-CoV-2, scientists say. 'This approach is compatible with many protein-based vaccines, so it offers the opportunity to engineer new formulations for these types of vaccines across a wide range of different diseases, such as influenza, Sars-CoV-2, or other pandemic outbreaks,' said Christopher Love, a co-author of the study from MIT. Adjuvants are commonly given along with vaccines to help stimulate a stronger immune response against proteins present on pathogens. For instance, protein-based vaccines like those for hepatitis A and B are delivered along with the adjuvant aluminium hydroxide, also known as alum, which helps the body form a stronger memory of the infectious agent. Scientists previously developed another adjuvant called saponin derived from the bark of the Chilean soapbark tree. Researchers have shown that a tiny nanoparticle formulation of saponin, along with an inflammation-promoting molecule called MPLA, can be used as an adjuvant for an HIV vaccine under trial. An alum and SMNP combination used as an adjuvant for the vaccine could generate even more powerful immune responses against HIV or SARS-CoV-2, scientists say. Scientists suspect this combination boosts the immune response, specifically via the body's B cells, which produce antibodies. They found that such a vaccine combination accumulated in the mice lymph nodes, causing their B cells to undergo rapid mutations to generate a mix of antibodies against HIV. Researchers showed that the SMNP and alum combination helped an HIV protein penetrate through a protective layer of cells around the lymph nodes without being broken down. 'As a result, the B cells that are cycling in the lymph nodes are constantly being exposed to the antigen over that time period, and they get the chance to refine their solution to the antigen,' Dr Love explained. Scientists liken this process to what occurs during a natural infection, when antigens can remain in the lymph nodes for weeks, giving the body time to mount an immune response. 'What's potentially powerful about this approach is that you can achieve long-term exposures based on a combination of adjuvants that are already reasonably well-understood, so it doesn't require a different technology,' Dr Love said. 'It's just combining features of these adjuvants to enable low-dose or potentially even single-dose treatments,' he said.
Scottish Sun
3 hours ago
- Scottish Sun
Tragic cancer-stricken girl, 7, who fled wartorn Ukraine for leukaemia treatment in Israel killed in Iran missile blitz
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) A SEVEN-year-old girl who fled the war in Ukraine to receive life-saving leukaemia treatment in Israel has been tragically killed. Nastia Borik, her grandmother and two young cousins were all reported dead following the Iranian blitz on a Bat Yam apartment building in Tel Aviv on Sunday. Sign up for Scottish Sun newsletter Sign up 6 Nastia Borik was tragically killed after going to Israel to seek life-changing surgery for her leukaemia 6 Members of Israel's Home Front Command search for missing people under the rubble of apartment block Bat Yam Credit: EPA 6 A huge column of smoke rises from Soroka Hospital in Beersheba Her mother Maria Peshkurova, 30, remains missing, the Times of Israel reports. The attack, which is believed to have wounded 180 people and killed at least six, comes amid six nights of heavy missile exchange between the two warring countries. Nastia Borik arrived in Israel in 2022 with her mother, grandmother, Lena Peshkurova, 60, and two of her cousins, Konstantin Totvich, 9, and Ilya Peshkurov, 13, to seek life-saving treatment for Leukemia. The girl's father, Artem, reportedly stayed in Ukraine to fight in the war against Russia. He could not accompany his daughter due to a government order barring men under the age of 60 from leaving the country during the conflict. Her tragic killing comes as tensions between Israel and Iran have reached cataclysmic heights, as a major Israeli hospital and an Iranian nuclear reactor were both blitzed this morning. Soroka Hospital in Beersheba was severely damaged when it was struck by an Iranian ballistic missile, with Israel reporting around 70 casualties overnight - some serious. The IDF confirmed it attacked an "inactive" plutonium nuclear reactor in Arak to "prevent it from being restored and used for nuclear weapons". After days of speculation, Trump on Tuesday night approved plans to attack Iran, but is holding off in case Tehran agrees to abandon its nuclear programme, reports the Wall Street Journal. If given the go-ahead, the plans would see the US join Israel in pounding Iran's nuke sites - which Tehran has warned would spark "all out war". Chilling vid shows Israeli school bus blown to bits by Iranian missile in madcap Ayatollah's death-throw retaliation The UK is yet to declare whether it would stand with the US should Trump decide to go ahead with military action. But Sir Keir Starmer has been warned by Attorney General Lord Hermer that the UK's involvement could be illegal. It comes as Sir Keir held a Cobra crisis meeting on Wednesday with a potential US-led strike reportedly being discussed. Trump has become much more vocal on the conflict, though refuses to confirm his plans: "I may do it, I may not do it," he said on Wednesday. If the US does collaborate in the attacks, Iran's Fordow nuclear development area could be its first target. A fearsome 15-ton mega bomb known as a Massive Ordnance Penetrator (MOP) bomb could be used to strike the core of the plant, which Israel is unable to reach with its own weapons. Speaking to reporters from the Oval Office Trump acknowledged the US is the only nation capable of blitzing the key nuke site. But he added: "That doesn't mean I'm going to do it - at all." Trump also fired a two-word warning to Iran's Supreme Leader after revealing Tehran was trying to return to the negotiating table. When a White House reporter asked Trump about Ayatollah Ali Khamenei's declaration that he will "never surrender", Trump simply responded: "Good luck." Trump even directly threatened Khamenei as he said the US knows where he is hiding but will not kill him 'for now'. Khamenei responded by saying: "The battle begins. This nation will never surrender. 'America should know that any military intervention will undoubtedly result in irreparable damage.' US officials indicated the next 24 to 48 hours will be crucial in determining whether diplomacy could ever be achieved with Iran, ABC News reports. It comes as warmongering Russia ironically warned the world sits "on the brink of catastrophe" as the raging Middle East conflict entered day six. 6 The war has entered its sixth day Credit: Alamy 6 Emergency and Rescue soldiers search for trapped people following Iran's overnight strikes Credit: Getty
